Navigation Links
AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
Date:10/3/2008

TUSTIN, Calif., Oct. 3 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, today announced that the Company will present at the Maxim Group Growth Investor Conference in New York City on Tuesday, October 7, 2008 at 10:30 a.m. ET. AMDL's presentation will be held at the Grand Hyatt New York Hotel in the Morosco Room.

The Maxim Group Growth Conference features interactive presentations and one-on-one meetings with executives from over 80 emerging growth companies within various sectors including healthcare and pharmaceuticals. Attendees include securities analysts, fund managers and institutional investors.

AMDL, Inc. is a specialty pharmaceutical Company devoted to the research, development, manufacturing, and marketing of over 180 diagnostic, pharmaceutical, nutritional supplement, and cosmetic products in China and outlying markets.

This year alone, the Company has secured over $25 million in sales contracts for its best-selling Goodnak(R) anti-aging product; expanded the Goodnak(R) revenue opportunity with the launch of two additional product formulations that include Goodnak(R) capsules and Goodnak(R) lotions; and secured US FDA clearance on July 3, 2008 for its ELISA DR-70(R) FDP cancer diagnostic test - the first test to be cleared by the US FDA in over 25 years for the monitoring of colorectal cancer.

These are a few milestones AMDL's Board Chairman and Audit Committee Chair Mr. Douglas MacLellan will highlight in a presentation which will also cover AMDL's market opportunity as an aggressively growing micro-cap investment opportunity in the China specialty pharmaceuticals sector. He will also provide insight on AMDL's growth strategy, product portfolio and 2008 financial projections. The presentation will be live-broadcast over the Internet and archived for 90 days. Interested parties may listen to the presentation by visiting the Investor Information section of the Company's website at: http://www.amdl.com .

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs approximately 320 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(M) (206) 310-5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
2. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
3. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
4. AMDL, Inc. Closes Private Placement of Convertible Notes
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... PA (PRWEB) , ... February 09, 2016 , ... Tunnell ... Europe. Based in Paris, he will focus on acquiring new accounts and work ... met. , “Fred brings to our European clients more than 15 ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, a ... for cancer, announced that its lead product, ... Commission as an orphan medicinal product for ... form of glioma, strikes approximately 25,000 people ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... , Feb. 9, 2016 BERG, a ... biological research approach, has announced the appointment of ... and Chief Operating Officer. Haddock brings to BERG ... including 12 years in senior financial functions at ... in business organizational management. Niven ...
(Date:2/8/2016)... , Feb. 8, 2016  CytRx Corporation ... development company specializing in oncology, today announced that ... security agreement with Hercules Technology Growth Capital, Inc. ... $40 million in financing. --> ... first $25 million of financing under the loan ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
Breaking Biology News(10 mins):